The Wave of Innovation in Synthetic Biology and Bio-Manufacturing: A New Turning Point for the Biotech Industry in 2026
Editor
Acceleration of the Bio-Manufacturing Revolution
In 2026, the biotech industry is experiencing unprecedented changes due to the convergence of synthetic biology and bio-manufacturing technologies. The global bio-manufacturing market has reached a scale of $542 billion this year, showing a 78% growth compared to 2021. The backdrop of this rapid growth includes the pressure to respond to climate change, the need for supply chain diversification, and, most importantly, the accelerated commercialization of synthetic biology technology. Particularly, bio-manufacturing processes utilizing microorganisms are analyzed to reduce carbon emissions by an average of 65% compared to traditional petrochemical-based production methods.
Korea’s bio-manufacturing ecosystem is also showing remarkable growth. Samsung Biologics, headquartered in Songdo, Gyeonggi Province, recorded a 34% increase in sales in the fourth quarter of 2025 compared to the same period last year, reaching 1.28 trillion won, further solidifying its position in the global biopharmaceutical contract manufacturing (CMO) market. The company currently operates facilities with a total production capacity of 620,000 liters, and with the completion of its fourth plant scheduled for the second half of 2026, it is expected to become the world’s largest biopharmaceutical production base. Celltrion in Incheon is also investing heavily in new drug development based on synthetic biology, leveraging its biosimilar manufacturing capabilities, and has set its R&D budget for 2025 at 420 billion won, a 28% increase from the previous year.
In the U.S. market, Boston-based Ginkgo Bioworks is establishing a unique positioning as a synthetic biology platform company. The company’s ‘Biological Foundry’ model provides customized microorganism design and optimization services according to client needs, with 2025 sales increasing by 67% from the previous year to $321 million. Notably, Ginkgo significantly enhanced its automation capabilities through the acquisition of Zymergen in 2024 and currently has the capacity to test 15,000 microorganism variants per month, which is evaluated to be about 100 times faster than traditional R&D methods.
Denmark’s enzyme specialist Novozymes (now merged into Novonesis) and the Netherlands’ DSM are establishing themselves as leaders in bio-manufacturing technology in the industrial enzyme and nutrient sectors, respectively. Novozymes reported a 23% increase in sales of enzymes for biofuels in 2025, reaching $1.8 billion, and announced a surge in demand for enzymes used in sustainable aviation fuel (SAF) production. DSM holds a 45% global market share in vitamin E production using synthetic biology technology and is actively investing in the development of plant-based protein alternatives.
Technological Breakthroughs and Accelerated Commercialization
The most significant change in the bio-manufacturing industry as of 2026 is the full-scale introduction of AI and machine learning technologies. Amyris, headquartered in Emeryville, California, announced that its ‘Lab-to-Market’ platform reduced the new product development period from the traditional 3-5 years to 18 months. The company achieved $684 million in sales in 2025 with products like squalene, vanillin, and artemisinin produced through synthetic biology technology, showing particular strength in the cosmetics raw materials sector. Amyris’s Brotas plant in Brazil has the capacity to produce 2 million liters of bio-based chemicals annually.
Notable technological advancements include the improved precision of the CRISPR-Cas system and the maturation of metabolic engineering technology. According to recent research, the success rate of microbial strain development as of 2026 has improved by 340% compared to 2020, attributed to the introduction of AI-based predictive modeling and automated screening systems. Particularly in bio-manufacturing using yeast and E. coli, the productivity of target compounds increased from an average of 85g to 230g per liter, evaluated to have surpassed the economic viability threshold.
Domestic researchers led by KAIST and Seoul National University are also achieving world-class results in bio-manufacturing technology development. Professor Sang Yup Lee’s team at KAIST announced in 2025 that they achieved the world’s highest yield in bio-plastic raw material production using E. coli, and this technology is currently undergoing commercialization verification through a pilot project with LG Chem. The Department of Chemical and Biological Engineering at Seoul National University developed a technology that improves the efficiency of biofuel production using microalgae by 2.3 times compared to existing methods, and is negotiating technology transfer with SK Innovation’s biofuel division.
Looking at global investment trends, venture capital investment in bio-manufacturing startups totaled $7.8 billion in 2025, a 12% increase from the previous year. Particularly, the average size of Series A investments expanded by 85% compared to 2020, reaching $28 million, indicating increased investor confidence in the maturity of the technology and market potential. In Asia, Korea, Singapore, and China are emerging as major hubs for bio-manufacturing investment, with active private investment linked to the Korean government’s ‘K-Bio Belt’ policy.
The growth of the industrial enzyme market is also noteworthy. The global industrial enzyme market is estimated to reach $9.2 billion by 2026, with enzymes for biofuels accounting for 28%, detergent enzymes for 22%, and food processing enzymes for 31%. Particularly, the price of cellulase enzymes has plummeted from $15 per kilogram in 2020 to $4.2 currently, analyzed as a result of advancements in mass production technology and intensified competition. This cost reduction significantly improves the economics of biofuels, and the International Energy Agency (IEA) announced that biofuels are expected to achieve price competitiveness with fossil fuels by 2027.
Another noteworthy area in bio-manufacturing technology is the production of alternative proteins through precision fermentation. Finland’s Solar Foods has commercialized innovative technology that produces protein using carbon dioxide and electricity from the air, and began operating its first commercial production facility in Europe in 2025. The company reduced the production cost of ‘Solein’ protein to $12 per kilogram and plans to further reduce it to $5 by 2027. The U.S.’s Perfect Day launched products such as ice cream and cheese using dairy proteins produced through precision fermentation, recording $230 million in sales in 2025.
Changes in the regulatory environment also significantly impact the growth of the bio-manufacturing industry. The U.S. FDA announced new guidelines for food ingredients produced through synthetic biology in November 2025, reducing the approval process by 30% compared to existing procedures. The European Union introduced carbon tax incentives for bio-based chemicals starting January 2026, further improving the price competitiveness of bio-manufacturing products. Korea’s Ministry of Food and Drug Safety also implemented the ‘Bio-Manufacturing Food Ingredient Approval Special Act’ in December 2025 to facilitate market entry for domestic bio-manufacturing companies.
Market Outlook and Investment Opportunities
The future outlook for the bio-manufacturing industry as of 2026 is very positive. According to McKinsey’s latest report, the global bio-manufacturing market is expected to maintain an average annual growth rate of 15.2% and reach a scale of $1.2 trillion by 2030. The chemical sector is expected to account for 40%, the pharmaceutical sector for 35%, and the food and feed sector for 25%. The Asia-Pacific region is expected to grow into the largest market, accounting for 45% of the total market, with China, Korea, India, and Singapore as the main growth drivers.
The trend to watch from an investment perspective is the vertical integration and platformization of bio-manufacturing companies. Ginkgo Bioworks acquired a total of 12 companies in 2025, building an integrated platform that encompasses the entire process from microorganism design to production and commercialization. The company’s market capitalization currently stands at $4.5 billion, an 80% increase from 2023. This platform strategy is evaluated as a model that simultaneously pursues market share expansion and profitability improvement by providing a one-stop solution to clients.
Korean companies are also accelerating their overseas expansion. Samsung Biologics announced in December 2025 the construction of a $2 billion biopharmaceutical production facility in Texas, USA, marking the largest overseas investment case by a Korean bio company. Celltrion is building a €1.5 billion production facility in the Netherlands to target the European biosimilar market, aiming to start operations in the first half of 2027. This global expansion demonstrates that domestic bio-manufacturing companies are growing into key players in the global biopharmaceutical value chain beyond simple contract manufacturing.
From a technological perspective, the field to watch after 2026 is the convergence of AI-based protein design and automated bio-foundries. Enzyme design using Google’s DeepMind AlphaFold technology has already entered the commercialization stage, and new enzymes developed through this are beginning to be utilized in industrial settings. Microsoft released ‘BioGPT-2’ in November 2025, unveiling a large-scale language model specialized for synthetic biology research, already being used by over 200 research institutions worldwide. The introduction of these AI technologies has reduced the development period for new microbial strains from six months to two months, and the success rate has significantly improved from 15% to 45%.
In terms of sustainability, the bio-manufacturing industry is recognized as a key means to achieve global carbon neutrality goals. The International Energy Agency estimates that the spread of bio-manufacturing technology could reduce annual CO2 emissions by 2.8 billion tons by 2030. This corresponds to about 6% of global greenhouse gas emissions. Particularly, significant contributions are expected in the fields of bio-plastics, biofuels, and bio-chemicals, with continuous expansion of government policy support and private investment anticipated.
However, challenges facing the bio-manufacturing industry still exist. The initial investment cost required to build large-scale production facilities remains high, with an average investment of $300-500 million needed for a 1 million-liter fermentation tank facility. Additionally, the shortage of skilled bioengineers and fermentation experts is intensifying, with the U.S. Bio-Manufacturing Association estimating that approximately 150,000 additional personnel will be needed by 2030. Regulatory uncertainty and consumer acceptance issues also remain challenges to be addressed. Nonetheless, considering the pace of technological advancement and increasing market demand, the bio-manufacturing industry is expected to continue its growth beyond 2026, offering attractive opportunities for investors and companies.
This analysis is for informational purposes only and is not an investment recommendation or advice. Please consult a professional before making investment decisions.
